Gross margin
86.2% Fiscal year 2025
Rank 96 of 100: higher than 96% of 153 peers (All). strong.
Rank 93 of 100: higher than 93% of 20 peers (Sector). strong.
Median Health Care: 66.6%
Share of revenue left after the direct cost of the products sold.
About the company
Vertex Pharmaceuticals is a US biotech company. It is known for cystic fibrosis drugs that treat the cause of the disease. It also offers a gene therapy for sickle cell disease and a non-opioid painkiller. It sells mainly in the US and Europe. As of Oct 11, 2026
Fact sheet (from the annual report) Pharmaceutical manufacturers · Boston, USA
According to the company, it is a global biotechnology company focused on specialty markets and operates in a single segment. It has approved medicines for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain. For cystic fibrosis, the group markets ALYFTREK, TRIKAFTA and KALYDECO, among others. JOURNAVX has been approved in the United States since January 2025 for treating moderate to severe acute pain in adults. For sickle cell disease and transfusion-dependent beta thalassemia, the group offers CASGEVY; in certain markets it can supply it directly to treatment centers. Customers are mainly a few specialty pharmacies and specialty distributors as well as certain large wholesalers in the US market.
Automatically summarized from SEC annual report (10-K, filed Feb 13, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026
Price performance at a glance
Last 30 trading days
- Today +0.7%
- 7 days +1.2%
- 30 days −1.0%
- 1 year +24.0%
Day range (last trading day)
−2.3%Price at 97% of the range+0.1%
52-week range
−22.6%Price at 75% of the range+7.5%
- Distance from the all-time high
- −7.0%
Our own calculation from the exchange’s daily candles, as of Oct 27, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.
Fundamentals · Analysis method
Growth, margin and debt compared with the sector – in detail in the fundamental analysis further down. The chart shows the candles without a buy zone.
Growth: greenMargin: greenDebt: gray
Fundamental analysis
SEC filing (10-K, 10-Q)Required reports of listed companies to the US Securities and Exchange Commission (SEC): 10-K is the annual report, 10-Q the quarterly report, 20-F the annual report of foreign companies. We show the figures of the first filing.Example: 10-K for the fiscal year ending Sep 27, 2025, filed on Oct 31, 2025.More in the Academy: Lesson revenue, profit and marginVertex Pharmaceuticals · Sector Health Care · amounts in USD
Information only – does not affect the other analysis methods, not investment advice. Source: SEC filings, As of Feb 13, 2026.
Quality checks
Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.
Fiscal year to Dec 31, 2025
Quality
Profitability, consistency, balance sheet
6 of 8 criteria met
Growth
Revenue and earnings per share
7 of 7 criteria met
Dividend
Level, consistency, coverage · 6 without data
0 of 1 criteria met
Financial strength
Piotroski, debt, liquidity · 2 without data
4 of 4 criteria met
Quality 6 of 8 met
- met: Gross margin above 40% 86.2%
- met: Operating margin above 15% 34.8%
- met: Net margin above 10% 32.9%
- met: Return on equity above 15% 21.2%
- met: Free cash flow margin above 10% 26.6%
- not met: Profit in each of the last 5 fiscal years 4 of 5
- not met: Free cash flow positive in each of the last 3 fiscal years 2 of 3
- met: Equity ratio above 30% 72.8%
Operating margin
34.8% Fiscal year 2025
Rank 86 of 100: higher than 86% of 192 peers (All). strong.
Rank 93 of 100: higher than 93% of 20 peers (Sector). strong.
Median Health Care: 18.0%
Operating income divided by revenue: what the core business earns before interest and taxes.
Net margin
32.9% Fiscal year 2025
Rank 90 of 100: higher than 90% of 237 peers (All). strong.
Rank 94 of 100: higher than 94% of 26 peers (Sector). strong.
Median Health Care: 13.9%
Profit after all costs, interest and taxes divided by revenue.
Return on equity
21.2% Fiscal year 2025
Rank 59 of 100: higher than 59% of 218 peers (All). medium.
Rank 69 of 100: higher than 69% of 21 peers (Sector). strong.
Median Health Care: 14.3%
Net income divided by equity at fiscal year end.
Return on assets
15.4% Fiscal year 2025 (total assets at year end)
Rank 85 of 100: higher than 85% of 238 peers (All). strong.
Rank 90 of 100: higher than 90% of 26 peers (Sector). strong.
Median Health Care: 6.4%
Net income divided by total assets at fiscal year end.
Equity ratio
72.8% Fiscal year 2025
Rank 91 of 100: higher than 91% of 239 peers (All). strong.
Rank 87 of 100: higher than 87% of 26 peers (Sector). strong.
Median Health Care: 38.5%
Equity as a share of total assets. Usually low for banks.
Free cash flow margin
26.6% Fiscal year 2025
Rank 79 of 100: higher than 79% of 213 peers (All). strong.
Rank 82 of 100: higher than 82% of 25 peers (Sector). strong.
Median Health Care: 14.9%
Free cash flow divided by revenue.
Free cash flow
3.2B USD Fiscal year 2025
Operating cash flow minus capital expenditure on property and equipment.
Growth 7 of 7 met
- met: Over 3 years, revenue grew by more than 5% per year +10.4%
- met: Over 5 years, revenue grew by more than 5% per year +14.1%
- met: Over 10 years, revenue grew by more than 5% per year +27.8%
- met: Over 3 years, EPS grew by more than 5% per year +6.1%
- met: Over 5 years, EPS grew by more than 5% per year +8.3%
- met: Revenue rose in at least 4 of the last 5 fiscal years 5 of 5
- met: Revenue rose in the last fiscal year +8.9%
Revenue growth 3 years
+10.4% per year
Rank 58 of 100: higher than 58% of 230 peers (All). medium.
Rank 66 of 100: higher than 66% of 25 peers (Sector). medium.
Median Health Care: +5.6%
Average growth per year over 3 fiscal years.
Revenue growth 5 years
+14.1% per year
Rank 61 of 100: higher than 61% of 217 peers (All). medium.
Rank 78 of 100: higher than 78% of 25 peers (Sector). strong.
Median Health Care: +8.5%
Average growth per year over 5 fiscal years.
Revenue growth 10 years
+27.8% per year
Rank 94 of 100: higher than 94% of 157 peers (All). strong.
Rank 87 of 100: higher than 87% of 19 peers (Sector). strong.
Median Health Care: +10.1%
Average growth per year over 10 fiscal years.
EPS growth 3 years
+6.1% per year
Rank 35 of 100: higher than 35% of 157 peers (All). medium.
Rank 57 of 100: higher than 57% of 22 peers (Sector). medium.
Median Health Care: +5.5%
Growth of earnings per share per year, adjusted for stock splits.
EPS growth 5 years
+8.3% per year
Rank 33 of 100: higher than 33% of 146 peers (All). medium.
Rank 63 of 100: higher than 63% of 20 peers (Sector). medium.
Median Health Care: +7.0%
Growth of earnings per share per year, adjusted for stock splits.
Dividend 0 of 1 met · 6 without data
- not met: Pays a dividend no dividend per share reported for the last fiscal year
- no data: Payout ratio at most 60% of earnings pays no dividend
- no data: Dividend paid in each of the last 5 fiscal years pays no dividend
- no data: Dividend per share never lowered in the last 5 fiscal years pays no dividend
- no data: Dividend per share higher than 5 years ago pays no dividend
- no data: Free cash flow per share covers the dividend pays no dividend
- no data: Dividends paid over the last 5 years covered by free cash flow pays no dividend
Financial strength 4 of 4 met · 2 without data
- no data: Piotroski F-Score at least 7 of 9 too many criteria without data 6 of 8 · 1 without data
- no data: Long-term debt no higher than equity no long-term debt reported
- met: Current assets cover current liabilities 2.90
- met: Positive equity 18.7B USD
- met: In 5 years, share count up by at most 5% −2.0%
- met: Free cash flow positive in the last fiscal year 3.2B USD
Piotroski F-Score
6 of 8 Fiscal year 2025
No rank: not all 9 criteria have data.
Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.
Liquidity (current ratio)
2.90 at fiscal year end
Rank 81 of 100: higher than 81% of 215 peers (All). strong.
Rank 79 of 100: higher than 79% of 26 peers (Sector). strong.
Median Health Care: 1.56
Current assets divided by current liabilities.
Change in share count
−2.0% in 5 years
Rank 51 of 100: lower than 51% of 199 peers (All). medium.
Rank 44 of 100: lower than 44% of 24 peers (Sector). medium.
Median Health Care: −2.7%
Change in diluted share count. Negative = share buybacks, positive = new shares.
The 9 criteria of the Piotroski F-Score
- met: Profit in the last fiscal year (positive return on assets)
- met: Positive operating cash flow
- met: Return on assets higher than the prior year
- not met: Operating cash flow higher than net income
- no data: Long-term debt relative to total assets fell
- met: Liquidity (current assets / current liabilities) rose
- not met: No additional shares (diluted share count did not rise)
- met: Gross margin higher than the prior year
- met: Revenue relative to total assets higher than the prior year
Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.
Price-based criteria (P/E, dividend yield) are shown to signed-in users.
Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.
In short
- Light green: Revenue grew over 5 years (+14.1% per year), at least as fast as the sector median.
- Light green: Net income (total) grew over 5 years (+7.8% per year), at least as fast as the sector median; per share +8.3% per year.
- Light green: Net margin 32.9%, above the sector median (12.9%).
- Light red: Profit in 8 of 10 fiscal years.
Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.
- Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 1.7B USD · Net income −112.1M USD · Net margin −6.6%
- Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 2.5B USD · Net income 263.5M USD · Net margin 10.6%
- Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 3.0B USD · Net income 2.1B USD · Net margin 68.8%
- Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 4.2B USD · Net income 1.2B USD · Net margin 28.3%
- Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 6.2B USD · Net income 2.7B USD · Net margin 43.7%
- Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 7.6B USD · Net income 2.3B USD · Net margin 30.9%
- Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 8.9B USD · Net income 3.3B USD · Net margin 37.2%
- Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 9.9B USD · Net income 3.6B USD · Net margin 36.7%
- Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 11.0B USD · Net income −535.6M USD · Net margin −4.9%
- Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 12.0B USD · Net income 4.0B USD · Net margin 32.9%
- Quarter Q3/23 (Jul 1, 2023 – Sep 30, 2023): Revenue 2.5B USD · Net income 1.0B USD · Net margin 41.7%
- Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Revenue 2.5B USD · Net income 968.8M USD · Net margin 38.5% · Q4 derived (year minus 9 months), may be distorted by restatements
- Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Revenue 2.7B USD · Net income 1.1B USD · Net margin 40.9%
- Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Revenue 2.6B USD · Net income −3.6B USD · Net margin −135.8%
- Quarter Q3/24 (Jul 1, 2024 – Sep 30, 2024): Revenue 2.8B USD · Net income 1.0B USD · Net margin 37.7%
- Quarter Q4/24 (Oct 1, 2024 – Dec 31, 2024): Revenue 2.9B USD · Net income 913.0M USD · Net margin 31.4% · Q4 derived (year minus 9 months), may be distorted by restatements
- Quarter Q1/25 (Jan 1, 2025 – Mar 31, 2025): Revenue 2.8B USD · Net income 646.3M USD · Net margin 23.3%
- Quarter Q2/25 (Apr 1, 2025 – Jun 30, 2025): Revenue 3.0B USD · Net income 1.0B USD · Net margin 34.8%
- Quarter Q3/25 (Jul 1, 2025 – Sep 30, 2025): Revenue 3.1B USD · Net income 1.1B USD · Net margin 35.2%
- Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Revenue 3.2B USD · Net income 1.2B USD · Net margin 37.3% · Q4 derived (year minus 9 months), may be distorted by restatements
- Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Revenue 3.0B USD · Net income 1.0B USD · Net margin 34.5%
- Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Revenue 3.3B USD · Net income 1.1B USD · Net margin 33.0%
- Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Earnings per share −0.46 USD
- Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Earnings per share 1.04 USD
- Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Earnings per share 8.09 USD
- Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Earnings per share 4.51 USD
- Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Earnings per share 10.29 USD
- Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Earnings per share 9.01 USD
- Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Earnings per share 12.82 USD
- Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Earnings per share 13.89 USD
- Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Earnings per share −2.08 USD
- Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Earnings per share 15.32 USD
- Quarter Q3/23 (Jul 1, 2023 – Sep 30, 2023): Earnings per share 3.97 USD
- Quarter Q4/23 (Oct 1, 2023 – Dec 31, 2023): Earnings per share not reported separately for Q4
- Quarter Q1/24 (Jan 1, 2024 – Mar 31, 2024): Earnings per share 4.21 USD
- Quarter Q2/24 (Apr 1, 2024 – Jun 30, 2024): Earnings per share −13.92 USD
- Quarter Q3/24 (Jul 1, 2024 – Sep 30, 2024): Earnings per share 4.01 USD
- Quarter Q4/24 (Oct 1, 2024 – Dec 31, 2024): Earnings per share not reported separately for Q4
- Quarter Q1/25 (Jan 1, 2025 – Mar 31, 2025): Earnings per share 2.49 USD
- Quarter Q2/25 (Apr 1, 2025 – Jun 30, 2025): Earnings per share 3.99 USD
- Quarter Q3/25 (Jul 1, 2025 – Sep 30, 2025): Earnings per share 4.20 USD
- Quarter Q4/25 (Oct 1, 2025 – Dec 31, 2025): Earnings per share not reported separately for Q4
- Quarter Q1/26 (Jan 1, 2026 – Mar 31, 2026): Earnings per share 4.02 USD
- Quarter Q2/26 (Apr 1, 2026 – Jun 30, 2026): Earnings per share 4.31 USD
No reported values for “Dividend per share” in this interval.
No reported values for “Dividend per share” in this interval.
Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 12.0B USD · Net income 4.0B USD · Net margin 32.9%
Figures over time
Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.
Money flow in fiscal year 2025
Of 100 USD of revenue, 86.2 USD gross profit, 34.8 USD operating income and 32.9 USD net income remained.
Money flow as a table
| Item | Amount | of revenue |
|---|---|---|
| Revenue | 12.0B USD | 100.0% |
| Gross profit | 10.4B USD | 86.2% |
| Cost of revenue | 1.7B USD | 13.8% |
| Operating income | 4.2B USD | 34.8% |
| Research & development | 3.9B USD | 32.6% |
| Other operating expenses | 2.3B USD | 18.9% |
| Net income | 4.0B USD | 32.9% |
| Interest expense | 13.3M USD | 0.1% |
| Taxes & other (net) | 206.8M USD | 1.7% |
Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.
Margins
The operating margin fell in 5 years from 46.0% to 34.8%.
Gross marginOperating marginNet margin- Fiscal year 2016: Gross margin not available · Operating margin 0.6% · Net margin −6.6%
- Fiscal year 2017: Gross margin not available · Operating margin 5.0% · Net margin 10.6%
- Fiscal year 2018: Gross margin not available · Operating margin 20.8% · Net margin 68.8%
- Fiscal year 2019: Gross margin 86.8% · Operating margin 28.8% · Net margin 28.3%
- Fiscal year 2020: Gross margin 88.1% · Operating margin 46.0% · Net margin 43.7%
- Fiscal year 2021: Gross margin 88.1% · Operating margin 36.7% · Net margin 30.9%
- Fiscal year 2022: Gross margin 87.9% · Operating margin 48.2% · Net margin 37.2%
- Fiscal year 2023: Gross margin 87.2% · Operating margin 38.8% · Net margin 36.7%
- Fiscal year 2024: Gross margin 86.1% · Operating margin −2.1% · Net margin −4.9%
- Fiscal year 2025: Gross margin 86.2% · Operating margin 34.8% · Net margin 32.9%
Returns
Return on equity fell in 5 years from 31.2% to 21.2%.
Return on equityReturn on assets- Fiscal year 2016: Return on equity −9.7% · Return on assets −3.9%
- Fiscal year 2017: Return on equity 13.0% · Return on assets 7.4%
- Fiscal year 2018: Return on equity 47.3% · Return on assets 33.6%
- Fiscal year 2019: Return on equity 19.3% · Return on assets 14.1%
- Fiscal year 2020: Return on equity 31.2% · Return on assets 23.1%
- Fiscal year 2021: Return on equity 23.2% · Return on assets 17.4%
- Fiscal year 2022: Return on equity 23.9% · Return on assets 18.3%
- Fiscal year 2023: Return on equity 20.6% · Return on assets 15.9%
- Fiscal year 2024: Return on equity −3.3% · Return on assets −2.4%
- Fiscal year 2025: Return on equity 21.2% · Return on assets 15.4%
Equity and long-term debt
The equity ratio fell in 5 years from 73.9% to 72.8%.
EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.- Fiscal year 2016: Equity 1.2B USD · Long-term debt 0.0 USD
- Fiscal year 2017: Equity 2.0B USD · Long-term debt not available
- Fiscal year 2018: Equity 4.4B USD · Long-term debt not available
- Fiscal year 2019: Equity 6.1B USD · Long-term debt not available
- Fiscal year 2020: Equity 8.7B USD · Long-term debt not available
- Fiscal year 2021: Equity 10.1B USD · Long-term debt not available
- Fiscal year 2022: Equity 13.9B USD · Long-term debt not available
- Fiscal year 2023: Equity 17.6B USD · Long-term debt not available
- Fiscal year 2024: Equity 16.4B USD · Long-term debt not available
- Fiscal year 2025: Equity 18.7B USD · Long-term debt not available
Liquidity (current ratio)
The current ratio fell in 5 years from 4.33 to 2.90.
Current ratio- Fiscal year 2016: Current ratio 2.31
- Fiscal year 2017: Current ratio 3.28
- Fiscal year 2018: Current ratio 3.43
- Fiscal year 2019: Current ratio 3.61
- Fiscal year 2020: Current ratio 4.33
- Fiscal year 2021: Current ratio 4.46
- Fiscal year 2022: Current ratio 4.83
- Fiscal year 2023: Current ratio 3.99
- Fiscal year 2024: Current ratio 2.69
- Fiscal year 2025: Current ratio 2.90
Cash flow
Free cash flow rose in 5 years from 3.0B USD to 3.2B USD.
Operating cash flowCapital expenditureFree cash flow in USD- Fiscal year 2016: Operating cash flow 236.1M USD · Capital expenditure 56.6M USD · Free cash flow 179.5M USD
- Fiscal year 2017: Operating cash flow 844.9M USD · Capital expenditure 99.4M USD · Free cash flow 745.5M USD
- Fiscal year 2018: Operating cash flow 1.3B USD · Capital expenditure 95.5M USD · Free cash flow 1.2B USD
- Fiscal year 2019: Operating cash flow 1.6B USD · Capital expenditure 75.5M USD · Free cash flow 1.5B USD
- Fiscal year 2020: Operating cash flow 3.3B USD · Capital expenditure 259.8M USD · Free cash flow 3.0B USD
- Fiscal year 2021: Operating cash flow 2.6B USD · Capital expenditure 235.0M USD · Free cash flow 2.4B USD
- Fiscal year 2022: Operating cash flow 4.1B USD · Capital expenditure 204.7M USD · Free cash flow 3.9B USD
- Fiscal year 2023: Operating cash flow 3.5B USD · Capital expenditure 200.4M USD · Free cash flow 3.3B USD
- Fiscal year 2024: Operating cash flow −492.6M USD · Capital expenditure 297.7M USD · Free cash flow −790.3M USD
- Fiscal year 2025: Operating cash flow 3.6B USD · Capital expenditure 437.6M USD · Free cash flow 3.2B USD
Share count
The share count fell in 5 years by 2.0% (mostly through share repurchases).
Diluted share count- Fiscal year 2016: Diluted share count 244.7M
- Fiscal year 2017: Diluted share count 253.2M
- Fiscal year 2018: Diluted share count 259.2M
- Fiscal year 2019: Diluted share count 260.7M
- Fiscal year 2020: Diluted share count 263.4M
- Fiscal year 2021: Diluted share count 259.9M
- Fiscal year 2022: Diluted share count 259.1M
- Fiscal year 2023: Diluted share count 260.5M
- Fiscal year 2024: Diluted share count 257.9M
- Fiscal year 2025: Diluted share count 258.0M
From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.
Dividends and share repurchases
How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.
- Dividend per share
- none pays no dividend
- To shareholders (5 years)
- 5.0B USD 100% through repurchases
- Share count over 5 years
- −2.0% fewer shares – each share is a larger stake
What goes back to shareholders
Over 5 years, 5.0B USD went back to shareholders, 100% of it through share repurchases. That is 42% of the free cash flow of those years.
Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD- Fiscal year 2016: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 179.5M USD
- Fiscal year 2017: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 745.5M USD
- Fiscal year 2018: Dividends paid not available · Share repurchases 350.0M USD · New shares issued (including employee plans) not available · Free cash flow 1.2B USD
- Fiscal year 2019: Dividends paid not available · Share repurchases 192.0M USD · New shares issued (including employee plans) not available · Free cash flow 1.5B USD
- Fiscal year 2020: Dividends paid not available · Share repurchases 539.1M USD · New shares issued (including employee plans) not available · Free cash flow 3.0B USD
- Fiscal year 2021: Dividends paid not available · Share repurchases 1.4B USD · New shares issued (including employee plans) not available · Free cash flow 2.4B USD
- Fiscal year 2022: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 3.9B USD
- Fiscal year 2023: Dividends paid not available · Share repurchases 427.6M USD · New shares issued (including employee plans) not available · Free cash flow 3.3B USD
- Fiscal year 2024: Dividends paid not available · Share repurchases 1.2B USD · New shares issued (including employee plans) not available · Free cash flow −790.3M USD
- Fiscal year 2025: Dividends paid not available · Share repurchases 2.0B USD · New shares issued (including employee plans) not available · Free cash flow 3.2B USD
Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.
Valuation over time
Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users. Log in
Sector comparison
Vertex Pharmaceuticals next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.
| Symbol | Revenue (FY) | Growth 5 yrs | Gross margin | Op. margin | Net margin | ROE | Equity ratio | FCF margin | Piotroski |
|---|---|---|---|---|---|---|---|---|---|
| ABT Abbott Laboratories | 44.3B USD | +5.1% | 56.4% | 18.2% | 14.7% | 12.5% | 60.1% | 16.7% | 6/9 |
| AMGN Amgen | 36.8B USD | +7.6% | 67.2% | 24.7% | 21.0% | 89.1% | 9.6% | 22.0% | 7/9 |
| MDT Medtronic | 36.4B USD | +3.8% | 65.0% | 17.8% | 13.2% | 9.7% | 53.2% | 14.9% | 7/9 |
| GILD Gilead Sciences | 29.4B USD | +3.6% | 78.8% | 34.0% | 28.9% | 37.5% | 38.5% | 32.1% | 8/9 |
| SYK Stryker Corporation | 25.1B USD | +11.8% | 64.0% | 19.5% | 12.9% | 14.5% | 46.9% | 17.1% | 6/9 |
| DHR Danaher Corporation | 24.6B USD | +2.0% | 59.1% | 19.1% | 14.7% | 6.9% | 62.9% | 21.4% | 7/9 |
| REGN Regeneron Pharmaceuticals | 14.3B USD | +11.0% | – | 24.9% | 31.4% | 14.4% | 77.1% | 28.4% | – |
| VRTX Vertex Pharmaceuticals this stock | 12.0B USD | +14.1% | 86.2% | 34.8% | 32.9% | 21.2% | 72.8% | 26.6% | – |
| ISRG Intuitive Surgical | 10.1B USD | +18.2% | 66.0% | 29.3% | 28.4% | 16.0% | 87.1% | 24.7% | – |
| Median of the sector 26 symbols | 44.4B USD | +8.5% | 66.6% | 18.0% | 13.9% | 14.3% | 38.5% | 14.9% | 7/9 |
Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).
Figures of the last fiscal year from SEC annual reports (peers as of Oct 28, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.
Key figures with traffic lights
Each light follows a simple, disclosed rule. The comparison is with the sector median Sector medianThe middle value of all companies in a sector: half are above it, half below. Unlike the average, single outliers hardly distort it.Example: Margins 4%, 8%, 10%, 12%, 60% → median 10%, average 18.8%.More in the Academy: Lesson putting the P/E in context of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).
Revenue growth
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth+14.1% per year, last 5 years
Sector Health Care: median +7.8% (60 symbols)
What does this mean? Revenue: over 5 years it grew by 14.1% per year on average – at least as fast as the median company in the sector (+7.8%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
Net income (total)
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth+7.8% per year, last 5 years
Sector Health Care: median +7.5% (46 symbols)
per share: +8.3% per year (5 years, split-adjusted)
What does this mean? Total net income: over 5 years it grew by 7.8% per year on average – at least as fast as the median company in the sector (+7.5%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
Net margin
Profit marginThe share of revenue that is left as profit after all costs.Example: Profit €60m on €500m revenue → margin 12%.More in the Academy: Lesson revenue, profit and margin32.9% last fiscal year
Sector Health Care: median 12.9% (63 symbols)
What does this mean? Of every 100 USD in revenue, 32.94 USD remained as profit – at least as much as the median company in the sector (12.9%). Five years ago the margin was 43.7%.
Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.
Debt / equity
Debt-to-equity ratioFinancial debt (loans, bonds) divided by equity. A high value amplifies good and bad years alike. The key figures bar in the chart only uses long-term financial debt.Example: Financial debt €300m, equity €500m → 0.6.More in the Academy: Lesson debt, dividends and growth– latest balance sheet
Sector Health Care: median 0.66 (49 symbols)
What does this mean? No usable figure: reported financial debt or positive equity for the same balance sheet date is missing.
Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.
Payout ratio
Payout ratioThe share of profit that a company pays out as a dividend. Above 100% it pays out more than it earns.Example: Dividend €1, earnings per share €2.50 → payout ratio 40%.More in the Academy: Lesson debt, dividends and growth– Dividend / earnings per share
Sector Health Care: median 28% (31 symbols)
What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.
Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.
Profitable years
Profitable yearsHow many of the last fiscal years ended with a profit rather than a loss on the bottom line. The figure shows how consistently a company earns.Example: Profit in 9 of 10 years → one loss year.More in the Academy: Lesson revenue, profit and margin8 of 10 fiscal years with a profit
What does this mean? In 8 of the last 10 fiscal years the bottom line showed a profit. 2 years ended with a loss.
Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).
All figures as a table
| Year | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| 2025 | Dec 31, 2025 | 12.0B | 4.0B | 32.9% | 15.32 | – | – |
| 2024 | Dec 31, 2024 | 11.0B | −535.6M | −4.9% | −2.08 | – | – |
| 2023 | Dec 31, 2023 | 9.9B | 3.6B | 36.7% | 13.89 | – | – |
| 2022 | Dec 31, 2022 | 8.9B | 3.3B | 37.2% | 12.82 | – | – |
| 2021 | Dec 31, 2021 | 7.6B | 2.3B | 30.9% | 9.01 | – | – |
| 2020 | Dec 31, 2020 | 6.2B | 2.7B | 43.7% | 10.29 | – | – |
| 2019 | Dec 31, 2019 | 4.2B | 1.2B | 28.3% | 4.51 | – | – |
| 2018 | Dec 31, 2018 | 3.0B | 2.1B | 68.8% | 8.09 | – | – |
| 2017 | Dec 31, 2017 | 2.5B | 263.5M | 10.6% | 1.04 | – | – |
| 2016 | Dec 31, 2016 | 1.7B | −112.1M | −6.6% | −0.46 | – | – |
| Quarter | End | Revenue | Net income | Margin | Earnings per share | Dividend per share | Payout |
|---|---|---|---|---|---|---|---|
| Q2/26 | Jun 30, 2026 | 3.3B | 1.1B | 33.0% | 4.31 | – | – |
| Q1/26 | Mar 31, 2026 | 3.0B | 1.0B | 34.5% | 4.02 | – | – |
| Q4/25* | Dec 31, 2025 | 3.2B | 1.2B | 37.3% | – | – | – |
| Q3/25 | Sep 30, 2025 | 3.1B | 1.1B | 35.2% | 4.20 | – | – |
| Q2/25 | Jun 30, 2025 | 3.0B | 1.0B | 34.8% | 3.99 | – | – |
| Q1/25 | Mar 31, 2025 | 2.8B | 646.3M | 23.3% | 2.49 | – | – |
| Q4/24* | Dec 31, 2024 | 2.9B | 913.0M | 31.4% | – | – | – |
| Q3/24 | Sep 30, 2024 | 2.8B | 1.0B | 37.7% | 4.01 | – | – |
| Q2/24 | Jun 30, 2024 | 2.6B | −3.6B | −135.8% | −13.92 | – | – |
| Q1/24 | Mar 31, 2024 | 2.7B | 1.1B | 40.9% | 4.21 | – | – |
| Q4/23* | Dec 31, 2023 | 2.5B | 968.8M | 38.5% | – | – | – |
| Q3/23 | Sep 30, 2023 | 2.5B | 1.0B | 41.7% | 3.97 | – | – |
* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.
How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.
Insiders
Insider transactionsExecutives, directors and major shareholders (over 10%) of US companies report their own transactions in their company’s stock to the SEC within two business days (Form 4). Purchases in the market count as more meaningful than sales (often taxes, estate planning).Example: Three executives acquire stock worth a total of 2 million USD within two weeks → “purchases by several insiders”.More in the Academy: Glossary| Period | Purchases | Sales | Net |
|---|---|---|---|
| 3 months | $00 people | $00 people | $0 |
| 6 months | $00 people | $11.0M6 people | −$11.0M |
| 12 months | $00 people | $158.1M13 people | −$158.1M |
Latest transactions
- Jul 2, 2026 Tatsis Ourania Officer Open-market sale · 10b5-1 plan 1,500 shares · $787.5K · SEC
- Jul 2, 2026 McKechnie Duncan Officer Open-market sale · 10b5-1 plan 1,541 shares · $799.8K · SEC
- Jul 1, 2026 Liu Joy Officer Open-market sale · 10b5-1 plan 828 shares · $416.2K · SEC
- Jun 26, 2026 Bozic Carmen Officer Open-market sale · 10b5-1 plan 596 shares · $287.6K · SEC
- Jun 18, 2026 Bozic Carmen Officer Open-market sale · 10b5-1 plan 1,020 shares · $471.4K · SEC
- Jun 15, 2026 Bozic Carmen Officer Open-market sale · 10b5-1 plan 4,062 shares · $1.8M · SEC
Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.
Trend score +65
Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+0
Highs and lows+0
Relative strength+15
Volatility and trend strength
ADX 14 (trend strength)16.3
Rel. strength 60 d+9.6%
ATR ATR (Average True Range)The average range per trading day over the last 14 days. It makes distances comparable, whether a stock costs 10 or 1,000.Example: ATR 2.50 at a price of 100: 0.4 ATR is 1.00, i.e. 1%.More in the Academy: Lesson ATR and moving averages as price values only when logged in.
More stocks from Health Care
News
Latest news
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? Yahoo Finance · Oct 27, 15:15
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? Finnhub · Yahoo · Oct 27, 15:15
BofA Names this Drugmaker a Top Pick on Promising Kidney Drug Data Yahoo Finance · Oct 27, 14:09
BofA Names this Drugmaker a Top Pick on Promising Kidney Drug Data Finnhub · Yahoo · Oct 27, 14:09
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why Yahoo Finance · Oct 26, 21:50
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why Finnhub · Yahoo · Oct 26, 21:50
BHC Q3 Earnings Preview: Here's What You Should Know Yahoo Finance · Oct 26, 18:33
BHC Q3 Earnings Preview: Here's What You Should Know Finnhub · Yahoo · Oct 26, 18:33
Posts
No posts on VRTX yet – log in to join the discussion.
Posts are opinions of users and only visible after logging in. Community rules